Objective: Arabinoxylan (AX) consumption is associated with metabolic improvement during diabetes and with modulation of ghrelin, an orexigenic gut hormone. The effect of AX consumption on ghrelin secretion in disturbed metabolic states is unknown. Therefore, we investigated the postprandial responses to AX consumption of serum glucose, insulin and triglycerides and plasma total and acylated ghrelin in subjects with impaired glucose tolerance (IGT). Design: Randomized, single-blind, controlled, crossover intervention trial. Subjects: Seven female and four male adults with IGT, aged 55.5 years, and body mass index (BMI) 30.1 kg/m 2 . Intervention: Subjects received either placebo or 15 g AX supplement for 6 weeks with a 6-week washout period in-between. Main outcome measurements: Postprandial responses of serum glucose, insulin and triglycerides, and plasma total and acylated ghrelin after a liquid meal challenge test (LMCT) measured at the beginning and at the end of the dietary intervention at À20, À5, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210 and 240 min. Results: After LMCT, AX consumption resulted in lower postprandial responses in serum glucose, insulin and triglycerides (Po0.05). Compared to placebo, total plasma ghrelin was also reduced by 4278 pg/ml (Po0.001) after AX consumption with no difference in plasma acylated ghrelin. Conclusion: AX consumption improved postprandial metabolic responses after an LMCT in subjects with IGT and reduced total ghrelin response. However, acylated ghrelin responses were unchanged, suggesting that the acylated ghrelin-mediated orexigenic regulation is not improved as only total plasma ghrelin decreased. Sponsorship: Federal Ministry of Education and Research Germany (PTJ-BIO/0313042C).
Introduction
Well-balanced diets rich in dietary fibre have beneficial effects on risk markers of the metabolic syndrome (Chandalia et al., 2000; Jang et al., 2001; McKeown et al., 2002; Pereira et al., 2002; Liese et al., 2003) . Dietary fibre can be classified according to its viscosity (Fernandez, 2001) . Numerous studies have shown that viscous dietary fibre reduces low-density lipoprotein (LDL) cholesterol (Brown et al., 1999; Onning et al., 1999; Anderson et al., 2000) and improves glycaemic control in type II diabetes (Brennan, 2005) . There is also increasing evidence that dietary fibre has also beneficial effects on long-term weight management (Slavin, 2005) .
A major component of dietary fibre in cereal grains is arabinoxylan (AX), a hemicellulose with a xylose backbone and arabinose side chains (Amodo and Neukom, 1985) that behaves physiologically like a soluble, viscous fibre (Lu et al., 2000a) . AX can be extracted from a byproduct of wheat flour processing for starch extraction (Meuser and Imhof, 2002) . The acute and mid-term ingestion of AX has been shown to improve postprandial glucose and insulin responses in normo-and hyperglycaemic subjects (Lueder et al., 1996; Lu et al., 2000b Lu et al., , 2004 . However, the mechanisms to explain the effects of dietary fibre on these metabolic responses are not known. Dietary fibre consumption reduces feelings of hunger, increases feelings of fullness and promotes satiety (Sparti et al., 2000; Slavin, 2005) , which suggests associations with the complex net of gut hormones regulating energy metabolism. Among these hormones, ghrelin, a peptide mainly produced and excreted in the stomach (Kojima et al., 1999) , is of increasing interest. Ghrelin is found in plasma in two major forms, acylated and desacyl ghrelin, which inversely effect the endocrine regulation of energy balance Chen et al., 2005) . During fasting, ghrelin concentration in plasma rises gradually and decreases immediately after food intake. When administered to mice, the acylated form (3-4% of total circulating ghrelin) induces a positive energy balance by promoting food intake and decreasing fat use (Tschop et al., 2000; Kojima and Kangawa, 2002) , whereas the desacyl form decreases food intake of mice by delaying gastric emptying . Ghrelin acts via hypothalamic mediation (Cowley et al., 2003) . Administration of acylated ghrelin to humans increased glucose levels and inhibited insulin secretion, whereas desacyl ghrelin antagonized these effects (Broglio et al., 2004) . Postprandial ghrelin responses in humans might be proportional to caloric content and dependent on macronutrient intake (Callahan et al., 2004; le Roux et al., 2005) . Little is known about the effects of dietary fibre intake on ghrelin secretion. Soluble dietary fibre consumption was shown to decrease total ghrelin levels in healthy women (Nedvidkova et al., 2003) , but we recently reported increased total ghrelin levels in plasma of normoglycaemic subjects after the acute ingestion of an AX-rich breakfast (Mohlig et al., 2005) . The effects of an AX intake for several weeks on subjects with impaired glucose tolerance (IGT) on total and acylated plasma ghrelin responses are unknown. Therefore, we investigated the effects of AX fibre consumption for 6 weeks on fasting serum glucose, insulin, lipids and plasma ghrelin as well as on postprandial responses after a liquid meal challenge test (LMCT) in subjects with IGT.
Methods

Subjects
Volunteers were recruited using local press and advertisements. Inclusion criteria were age between 20 and 70 years, body mass index (BMI) 426 kg/m 2 and impaired glucose tolerance (capillary glucose value at 120 min of the oral glucose tolerance test 47.8 mmol/l after 120 min). Exclusion criteria were infectious, gastrointestinal and chronic diseases or medical treatment (hyperlipidaemia, angiotensin converting enzyme (ACE)-inhibitor therapy, adrenocorticotrophic and/or thyroid drugs). Body weight was measured using an electronic scale to the nearest 0.1 kg (Soehnle, Murrhardt, Germany ). Screening was performed in 310 subjects. Fourteen (10 female and four male subjects) fulfilled the inclusion criteria and agreed to participate. All participants gave a written informed consent before starting the study. The Ethics Committee of the University of Potsdam approved the study protocol.
Experimental design
The study was designed as a single-blind, controlled, crossover intervention trial for 18 weeks. Subjects were randomly assigned to one of two treatment orders starting with control (placebo) or AX treatment. The foods and supplements were consumed within subject's habitual diet. Each dietary intervention lasted 6 weeks with a washout period of 6 weeks in-between. At 1 week before each intervention period, the subjects completed a 7-day physical activity record and a 4-day semiquantitative food record (Koebnick et al., 2005a, b) and were advised to follow their habitual diet and to maintain their habitual weight. Crossover took place after completion of the assigned intervention and wash out period. One subject did not complete the study and two subjects were excluded from the final analysis owing to acute infection with elevated C-reactive protein (410 mg/l; data not presented here).
At 1 day before and 1 day after each intervention, stimulation of the endogenous insulin secretion via LMCT and measurements of body composition using BOD POD s (Life Measurement Incorporated, Concord, CA, USA) were conducted. For body composition measurements, the subjects wore light clothing and a swim cup. Measurements were done according to the manufacturer's instructions. The coefficient of variation (n ¼ 14) was calculated as 0.6%.
Dietary intervention
The AX concentrate was produced by the Institute of Food Technology and Food Chemistry, Technical University Berlin. The extract contained 56.6% AX, 17% protein, 0.4% fat and the remaining to 100% of the total dry matter comprised of non-defined carbohydrates, like arabinogalactan and b-glucan. The concentrate had a molecular weight of 20-40 kDa, an intrinsic viscosity of 80 ml/g and an arabinose/xylose ratio of 0.8.
The AX intervention consisted of a 15 g AX supplement, provided as two white bread rolls (each containing 5 g AX concentrate) and as 5 g AX concentrate in powder form per day. The powder form could be mixed by volunteer's choice in any food (i.e. yoghurt, applesauce, juice, etc.). The placebo intervention was identical to the AX intervention but without AX enrichment (i.e. isocaloric rolls and powder). All bread rolls were prepared using standard recipes by a professional baker to assure similar flavour, colour and texture. Rolls were provided in frozen form for better storage.
Blood sampling and analyses Screening. For oral glucose tolerance test (oGTT), glucose was administered (75 g; Dextro OGT, Roche Diagnostic GmbH, Mannheim, Germany), followed by capillary blood glucose measurements every 30 min during 2 h. Capillary blood glucose concentrations from a hyperemic earlobe was determined in capillary whole blood with a glucose oxidasebased method (HemoCue glucose photometer, Ä ngelholm, Sweden). Serum insulin was measured using an insulin enzyme-linked immunosorbent assay (ELISA) (Mercodia, Uppsala, Sweden) with a negligible cross-reaction with Cpeptide of o0.01%, sensitivity o6 pmol/l. Intra-and interassay coefficient of variation (CV) were 4%. Homeostasis Model Assessment (HOMA-IR) was calculated as follows: fasting insulin (mU/ml) Â fasting glucose (mmol/l)/22.5 (Matthews et al., 1985) .
LMCT. For the LMCT, the volunteers consumed 400 ml of a standardized liquid meal (Biosorb Energie, PfrimmerNutricia, Erlangen, Germany) containing 2520 kJ, 73.6 g carbohydrates (49.3%), 24 g proteins (16%) and 23.2 g fat (34.7%) and no dietary fibre. All participants fasted for 12 h before arrival at the Institute's facilities. An in-dwelling venous catheter was inserted into the forearm vein for blood sampling. Fasting blood samples were obtained at À20, À5 and 0 min. Liquid meal was administered within 5 min. Blood samples were collected after 15, 30, 45, 60, 90, 120, 150, 180, 210 and 240 min for measurement of glucose, insulin, non-esterified fatty acids (NEFAs) and triglycerides in serum and every 30 min during 240 min for ghrelin measurements in plasma. Tubes containing a serum clot activator were used to obtain serum. Plasma was collected in tubes containing ethylenediaminetetraacetate (EDTA) and 150 ml Trasylol (Bayer Vital, Leverkusen, Germany). Serum was obtained after clotting at room temperature for 30 min, whereas plasma was collected immediately after centrifugation and was stabilized with 100 ml 1 N HCl in 1 ml. All samples were spun at 3000 U/min for 10 min at 41C and stored at À401C until analysed.
Serum glucose was measured in duplicate by the hexokinase method using commercially available colorimetric reagents (ADVIA 1650 Chemistry System, GLUH, Bayer, Leverkusen, Germany) with an intra-assay CV of 1.2%. Serum insulin was determined by ADVIA Centaur Immunoassay (Bayer, Leverkusen, Germany) with an intra-assay CV of 2.6%. Serum triglycerides were analysed using enzymatic colorimetric agents TRIG for ADVIA Chemistry System 1650 (Bayer, Leverkusen, Germany). The intra-assay CV was 1.2%. Serum NEFAs were analysed using ACS-ACOD-MEHA (Wako Chemicals, Neuss, Germany) with an interassay CV of 2.7%. Basal serum samples analyses for total cholesterol were measured using CHOD/PAP method (ABX Diagnostics Cholesterol, ABX Diagnostics, Montpellier, France) with an intra-assay CV of 0.82%. High-density lipoprotein (HDL) and LDL cholesterol were analysed using a commercially available kits in a PENTRA 400 analyser (Axon Laboratory, Reichenbach, Germany). Haemoglobin A1c (HbA1c) was determined using a Hi-Auto A1C HA-8140 system (A Menarini Diagnostics, Neuss, Germany).
Plasma total ghrelin was measured by a commercial available radio immunoassay (RIA), which utilizes 125 Ilabelled ghrelin and a ghrelin antiserum to determine the level of total ghrelin in plasma by double antibody/ polyethylenglycol technique (Linco Research, St Charles, MO, USA). The sensitivity of the method was 93 pg/ml. There was no cross-reaction with ghrelin 1-10, motilin-related peptide, glucagon, leptin or insulin. The intra-and interassay CVs were 10.0 and 14.7%, respectively. Percentage recovery was calculated with 96%. Plasma active ghrelin (acylated ghrelin) determination was performed using RIA that utilizes 125 I-labelled ghrelin as a tracer and an antibody (raised in guinea pigs) that is specific for the biological active form of ghrelin with the octanoyl group on serine 3 (Linco Research, MO, USA). The sensitivity of the method was 7.8 pg/ml. There was no cross-reaction with ghrelin 14-28, motilin-related peptide, glucagon, leptin or insulin. The intra-and inter-assay CVs were 6.7 and 9.6%, respectively. Percentage recovery was calculated with 114%.
Statistical analysis
All statistical analyses were performed using SAS 9.1 (SAS Institute Inc., Cary, NC, USA) and SPSS for Windows 11.5 (SPSS Inc., Chicago, IL, USA). General characteristics are given as mean7s.d. All other data, including figures, are presented as geometric means7geometric s.e.m. Mixed linear models were used to estimate effects of AX consumption. Subjects were included as a random factor. Residual analyses were conducted to control for violations of model assumptions. Fixed effects included in the final model were: baseline values, treatment, week (for postprandial responses: week 0 and week 6), time (for postprandial responses: t0 to t240) and changes in body weight (week 6 minus week 0).
Postprandial differences in plasma ghrelin and other parameters between AX and placebo treatment were calculated (AX-t0 -placebo-t0, AX-t30 -placebo-t30, etc). Intrasubject correlations between plasma ghrelin and other parameters were calculated based on these differences using 18 pairs of data (nine time points, two treatments) for 11 subjects. A P-value o0.05 was considered significant in all analyses.
Results
All participants were overweight, had slightly elevated total and LDL cholesterol and low HDL cholesterol concentrations (Table 1) . They were insulin resistant (defined as HOMA-IR42) and had an IGT (defined as capillary blood glucose 7.8-11.1 mmol/l after 120 min during oGTT). During the study period, dietary habits did not change with respect to energy intake, intake of fat, carbohydrates and protein as well as intake of dietary fibre (Table 2) . Mean body weight and body fat mass also showed no significant changes during the entire study period (Table 3) . However, changes in body weight ranged from À1.9 to 3.7 kg. Therefore, all analyses of AX effect are adjusted for changes in body weight.
Fasting serum concentrations of insulin, NEFA as well as plasma total and acylated ghrelin were not affected within 6 weeks of AX consumption (Table 3) . Serum triglycerides decreased slightly but significantly during AX consumption compared to placebo (P ¼ 0.047). Serum glucose increased slightly during placebo treatment and remained unchanged during AX consumption (P ¼ 0.022).
Following LMCT, postprandial responses of several parameters were significantly affected by consumption of AX. Serum glucose and insulin increased rapidly after liquid meal consumption (Po0.001), but postprandial response in serum glucose (P ¼ 0.005) and insulin (P ¼ 0.003) were lower after 6 weeks of AX consumption compared to placebo (Figure 1 ). This effect was independent of an adjustment for changes in body weight during the study period.
Serum triglycerides also increased after consumption of liquid meal (Po0.001), but postprandial response was lower after AX consumption compared to placebo (P ¼ 0.048; Figure 2 ). Serum NEFA decreased after consumption of liquid meal (Po0.001), but postprandial suppression was similar between both treatments (Figure 3) .
The consumption of AX for 6 weeks also affected postprandial ghrelin response. Plasma total ghrelin was significantly lower after AX consumption compared to placebo (4278 pg/ml; Po0.001; Figure 4 ). No suppression of plasma total ghrelin concentrations was observed after liquid meal consumption, but levels remained lower throughout entire postprandial observation period. This effect was independent of an adjustment for changes in body weight during the study period. Plasma acylated ghrelin decreased after liquid meal consumption (P ¼ 0.052), but postprandial response was not significantly different between both treatment regimens after adjustment for changes in body weight. Changes in plasma total (r ¼ 0.157; P ¼ 0.056) and acylated ghrelin (r ¼ 0.143; P ¼ 0.067) response during AX consumption and placebo were marginally correlated to changes in serum triglycerides. No correlations were observed between changes in plasma total and acylated ghrelin and changes in serum glucose, insulin and NEFA.
Discussion
The dietary intervention of the present study added 15 g of soluble dietary fibre, which means a 2.5-fold increase in soluble dietary fibre. The consumption of AX over 6 weeks significantly lowered the postprandial response of serum glucose, insulin and triglycerides. 6.0 (5.7-6.4) 6.3 (5.9-6.7) 5.4 (4.9-6.1) 5.4 (4.9-6.1) 0.029 Serum triglycerides (mmol/l) 1.5 (1. 3-1.7) 1.8 (1.6-2.1) 1.8 (1.6-2.0) 1.6 (1. Values are given as geometric mean and geometric standard error. b Significance of treatment effect based on differences during intervention periods (week 6-week 0). Mixed linear models include subject as random factor, treatment as fixed factor and values at week 0 and changes in body weight as a covariate (except models for body weight and fat). Abbreviations: AX, arabinoxylan; NEFA, non-esterified fatty acid. These effects may be related to the physicochemical properties of dietary fibre. Soluble dietary fibre intake increases viscosity of stomach content, delays gastric emptying and reduces the rate of starch digestion as well as the rate of glucose absorption (Brennan, 2005) . Delayed gastric emptying and nutrient absorption might result in lower postprandial glycaemic and lipidaemic responses. The consumption of soluble dietary fibre is associated with decreased postprandial glucose and insulin responses, reduction in ratings for hunger and desire to eat, as well as increased rates of fullness and satiety (Lavin and Read, 1995) .
Postprandial serum triglycerides response clearly declined after AX intervention but no effects were observed on serum NEFA concentrations. The lipid lowering action of soluble dietary fibre during hypercholesterolaemia (Anderson et al., 2000) and in type II diabetes (Pick et al., 1996) has been well documented. Dietary fibre intake has been associated with increased bile-acid excretion and increased activity of cholesterol 7a-hydrolase, which is a major enzyme in the pathway leading to cholesterol elimination in the body (Goel et al., 1999) . Dietary fibre interferes with the micellar solubility of lipids leading to decreased lipid absorption or a possible alteration on the rate and site of absorption (Schweizer and Wursch, 1991) . In addition, fermentation of dietary fibre results in changes in bile acid concentrations/ spectrum in the intestinal tract of rats, which is also related to its cholesterol-lowering effects (Dongowski et al., 2003) . The present study shows that AX consumption also decreases postprandial triglyceride levels. However, the mechanisms remain speculative.
In the present study, the postprandial decline in total and acylated ghrelin was not very pronounced in overweight subjects with impaired glucose tolerance, which is well in line with the published data. It has also been shown that the postprandial decline in ghrelin levels is less pronounced in obese compared to lean subjects (le Roux et al., 2005) , and insulin resistance measured by euglycaemic hyperinsulinemic clamp was described inversely related to the insulininduced decrease in total serum ghrelin levels (Lucidi et al., 2002) . This might explain the reduced decrease in postprandial total ghrelin response in insulin-resistant subjects as observed in the present study.
Nevertheless, the present study suggests that the chronic supplementation with AX for 6 weeks decreased total ghrelin levels constantly throughout the entire postprandial phase.
The response in acylated plasma ghrelin did not decrease after AX supplementation, a novel and unexpected result. Ghrelin acts to maintain body weight in a steady state and both molecular forms have counteracting roles with respect to energy balance (Korbonits et al., 2004; Asakawa et al., 2005) . Reductions in postprandial acylated ghrelin may lead to a decrease in food intake and thereby improve obesity and metabolic control. Moreover, the decrease in total ghrelin, but not in acylated plasma ghrelin suggests that desacyl ghrelin decreased, which is the major ghrelin isoform. Ghrelin is a gut hormone with multiple functions. Beyond regulation of energy balance, ghrelin has been shown to decrease blood pressure and to improve endothelial function (Peeters, 2005) . Therefore, the effects observed in the present study may be unfavourable with respect to medium-term weight management and other metabolic parameters. It has been recently reported that the maintenance of weight stability is associated with a certain number of adaptations (Tremblay et al., 2005) . Many of these adaptations have been related to insulin, which is an important regulator of energy expenditure and food intake. An increase in insulin facilitates the recovery of weight stability under conditions of long-term positive energy balance. A decrease of insulin in a reduced obesity state may lead to an increase in hunger and desire to eat (Tremblay and Doucet, 2000; Benoit et al., 2004; Strader and Woods, 2005) . Our results do not indicate that postprandial decline in ghrelin levels is mediated by insulin, which is in accordance with some (Purnell et al., 2003; Schaller et al., 2003) , but not all (Saad et al., 2002) previously performed studies. Ghrelin responses are modified by fat intake. Long-chain triglycerides exposure in the small intestine suppresses ghrelin secretion. The effects of the fat contents in the small intestine on ghrelin secretion occur progressively, indicating a modulatory mechanism that depends on the nutrient load and length of intestine exposed to nutrients (Feinle-Bisset et al., 2005) . Dietary fibre may also affect ghrelin secretion mediated by its effects on fat digestion. In our study, plasma total ghrelin levels were slightly associated with serum triglycerides, supporting the hypothesis that fat digestion is involved (Feinle-Bisset et al., 2005) . The decline in ghrelin as observed in the present study may be a further adaptive mechanism in obese subjects suffering from IGT and showing alterations in lipid metabolism. The mechanisms to explain our results remain elusive and further studies are needed to prove the results on a longterm basis. The effects of AX in the present study may also be caused by the use of dietary fibre isolates instead of whole grains where other bioactive compounds like phenolic acids may exert additional beneficial physiological effects (Eastwood and Kritchevsky, 2005) . However, the relevance of the reduction in plasma ghrelin observed in the present study on long-term weight management is not known.
The results reported here differ from our previous observations on the elevated total ghrelin response to a single AX-enriched breakfast. The differences may be explained by acute vs medium-term effects, the consistency of test meals and differences in the postprandial response between lean and obese subjects.
Limitations of the present study are the lack of long-term effects and the low sample size. However, the results of the present study are the results of a double-blind, controlled, randomized clinical study with crossover design, which allows to detect changes in postprandial response with sufficient power. Future studies are necessary to prove the effects observed in the present study in overweight subjects without impaired glucose tolerance as well as the effects in lean subjects. The quality of the AX used in the present study is comparable to the quality used in other studies with respect to purity and the arabinose/xylose ratio.
In conclusion, AX consumption for 6 weeks improves postprandial serum glucose, insulin and triglyceride response in overweight subjects with impaired glucose tolerance. Furthermore, this was associated with decreases in total plasma ghrelin concentrations, whereas the acylated form of ghrelin was unaffected.
